APP and Alzheimer disease: Iron‐chelating agents such as desferrioxamine can largely inhibit LPO of isolated brain tissues.[201] Pharmacologically inhibiting 12/15‐LOX can reverse AD‐like phenotype in a mouse model.[199] A recent study has shown that NADPH oxidase 4 (NOX4), a major source of ROS, was significantly elevated in impaired astrocytes of the cerebral cortex from patients with AD and the APP/PS1 double‐transgenic mouse model of AD.